Irvine, CA - A court injunction preventing the sale of Medtronic's CoreValve in Germany went into effect yesterday, the manufacturer of the CoreValve's chief competitor, Edwards Lifesciences, ...
Medtronic's CoreValve system today gained a second indication from the FDA for use in patients with severe aortic stenosis who are at high risk for surgery. The transcatheter aortic valve replacement ...
Add Yahoo as a preferred source to see more of our stories on Google. NEW YORK (AP) -- Medtronic said Monday that a federal appeals court has ruled it can continue selling its CoreValve heart valve ...
Siegburg, Germany - Percutaneous implantation of the self-expanding CoreValve aortic valve bioprosthesis in the first-ever series of patients shows that the procedure is feasible in those deemed too ...
The FDA today approved Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are unable to undergo conventional open-heart surgery.
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Use of transcaval access to perform transcatheter aortic valve replacement with the CoreValve ...
Meta-Analysis of Seven International Clinical Registries Presented at EuroPCR 2011 Late-Breaking Presentation PARIS – A late-breaking presentation about transcatheter aortic valve implantation (TAVI) ...
Approximately 1 in 3 patients with severe aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) with the CoreValve device will require a permanent pacemaker within 30 days of the ...
Market-Leading Transcatheter Aortic Valve Delivers Positive Clinical Outcomes Through Two Years in Major International Study; Achieves 10,000-patient Milestone PARIS--(BUSINESS WIRE)-- New clinical ...
MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Medtronic CoreValve® System to be delivered using direct aortic ...
MINNEAPOLIS--(BUSINESS WIRE)--Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc. (NYSE: MDT), today announced the start of the first of several new ...
Please provide your email address to receive an email when new articles are posted on . LONDON — Complications up to 3 years after transcatheter aortic valve implantation were infrequent in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results